Transcript

Dr. Tarantino: You mentioned that there is high-risk patients, but in truth, in the country and in general now in a setting of doing mammograms for screening, we’re catching more and more small tumors, stage one HER2-positive tumors. And there’s been, of course, a lot of interest in trying to adapt our regimens for this low-risk population. There was the APT trial showing that paclitaxel and trastuzumab led to outstanding outcomes at 10 years, which leading to the current standard, the ATEMPT study showing that T-DM1 leads to equally upstanding outcomes.

But now we saw also from China a very interesting phase two trial, IRIS-A, and I would love to hear Maryam’s thoughts, particularly since your interest into deescalating side effect of treatments. These were the trials that looked at adjuvant capecitabine trastuzumab for stage one HER2-positive breast cancer. 80% of patients had T1a disease, so very low risk, treated only with oral chemo trastuzumab, no IV chemo and there were no distant recurrences. There were only four events, a couple of which were just separate tumors, breast tumors.

And so, 98% five-year IDFS, are we ready to use this in the clinic? Which patients should get this or taxanes or would you want to replicate this? How are you thinking about this option?

Dr. Lustberg: I mean, I think it’s wonderful and it’s wonderful that we have these global trials being presented in this year’s ASCO, as in many other years. I think really thinking about the global oncology community, that I think this is important.

It is exciting that we are seeing data from Asian countries being presented. So with respect to these T1a HER2-positive tumors, we know that they do really well. There have been several datasets, including SEER data that have shown T1a tumors even without any type of treatment, have excellent prognosis. With the ER-negative HER2-positive tumor specifically, we do get a little bit more anxious and we’re more likely to consider treatment.

So in this study, the idea of a oral chemo regimen, they used intravenous Herceptin but we do have subcutaneous Herceptin. So if you can think of a completely intravenous-free regimen, that could be very attractive to some patients, including perhaps older patients who may want that ease, but certainly not ready for prime time. A phase-three study using this regimen is goin to be mounted in China, so we’ll await those results.

But I do think we currently do have the ATEMPT 2.0 study that is looking at six cycles of TDM versus Taxol Herceptin. So I think for patients where we do favor treatment, I think we have very good options right now in the US, and then we need to await some additional data about some of these alternative regimens.

But I think it’s intriguing. It’s intriguing to think about cape and Herceptin together. This body of IRIS study also will have an endocrine therapy Herceptin arm, as well as other combinations such as, I believe, Navelbine and Herceptin as well.

So I think to think more broadly about how we want to approach these very small HER2-positive tumors, I think overall is a good idea, but we also have good options now as well.

Dr. Tarantino: So many options coming. And if I can ask another follow-up question. So one key issue of taxane treatment that we use a lot, of course, is neuropathy, which can be potentially even permanent. We try to avoid that, but sometimes it does happen.

And so, one thing that has emerged lately is data with hands compression or cooling, in general lymph compression cooling. Is it something you’re doing at Yale that you recommend to patients?

Dr. Lustberg: So we are participating in the SWOG phase three study, which is looking at cryotherapy plus compression, compression alone or a very low dose compression. So we’re very committed to that phase three study.

But for patients who cannot do the study or there are other reasons that they may wanna go on their own, I think it’s important to describe the phase two data, body of phase two data studies that we have. They’re limited, but they do show some promise that cryo-compression can be helpful. But I do highlight the limitations of the data and that we do have phase three data coming.

I did poll our hematology oncology physicians group online and for the most part in this particular group, everybody was recommending cryo-compression to their patients.

Dr. Tarantino: And that’s great. At least if you have to give IV chemo, let’s try to make it as tolerated as possible.

So Maggie, I would like to utilize your translational expertise to understand among the many biomarkers that are emerging in this setting, which ones are ready for prime time. And so, Matt mentioned imaging biomarkers like PET scan, MRI scan, but then there’s CPA, some, as I say, already commercially available. There’s a lot of data with HER2DX, this gene signature, kind of the Oncotype DX for HER2-positive disease. What are we gonna do? Which one is ready for prime time, if any?

Dr. Gatti-Mays: So I do think that we are very smack dab in the middle of the age of biomarkers. And I think it’s great there’s a lot of different options, as you had mentioned. There’s obviously blood-based biomarkers, there’s imaging-based biomarkers.

However, I think at this point, there’s not really any that are truly ready for prime time or integration into the clinic. That being said is, I do think probably they’re coming and I’m eager to see kind of over the next few years. I anticipate especially many of these biomarkers work well in certain subgroups. And so, it really is trying to make sure that we’re using them in the appropriate populations.

I think ctDNA and especially the dynamic changes of ctDNA are something that we’re gonna see, not only in our HER2-positive patients, but really across the board. And I do think that there are still very important questions that need to be addressed in terms of the dynamics of these ctDNA assays, the sensitivity, specificity. But most importantly, if by intervening based on changes in these ctDNA assays, are we ultimately able to improve outcomes?

And that’s where I think too that, at least from what I’ve been seeing and looking at the data, I am optimistic that perhaps it may not be a single biomarker, but rather a compilation of biomarkers. So rather ctDNA and imaging together.

And I know that’s a lot of the newer trials have been incorporating that and I’m looking forward to that really it’s probably that combination that we’ll see rather than a single biomarker by itself.

Dr. Tarantino: I love this. I mean, all of them are promising. What if we could put them together? And I love the idea.

And Matt, I’m gonna instead ask you a very practical question. And I think we’ve been having kind of this issue of knowing that now T-DXd is approved both in the neoadjuvant and adjuvant setting. And so, we often discuss like, should we give it before or after surgery or both?

And so, the two practical questions I ask you is, if a patient seems to be eligible for DB-11, let’s say a T3N0 HER2-positive breast cancer, you’re negative, eligible for DB-11. Would you hit the T-DXd button upfront and do DB-11 or instead give taxane-based treatment and then give T-DXd if there is residual disease?

And the second question, I’m gonna make it very hard. If you decide to do DB-11, would you consider to use T-DXd if also after surgery or would you prefer whopping the payload and getting in T-DM1?

Dr. Kurian: Yeah, that’s the million dollar question, I would say. I think that the way that I look at it is, it’s excellent that we have both of these options now too. We’re curing folks that we never have cured before. So I think that that is the biggest takeaway that I would say, that we have great options for folks too.

But when you’re thinking about these options practically, you wanna make sure you deploy them in a way that’s gonna be perfect for the patient that you’re seeing as well too. And so if someone like that, a T3 tumor, obviously a little bit larger, but no nodal involvement, you could go either way, I think, with that.

I think you have to really sit down and talk about what both approaches look like, both neoadjuvantly and adjuvantly as well too. And I think to your point, I think why not give more T-DXd? We don’t have data for that, correct, right? But to say neoadjuvant and adjuvant, right? We don’t have that. But I think practically it makes sense.

But the thing I always come back to a little bit is that, the T-DXd alone arm, right? Did not give what we were looking for exactly there. So I think that I really personally gonna really be reserving this for those that have heavy nodal burden, larger tumors, inflammatory, the really bad actors up front that are at very high risk of metastases initially as well too.

But is it wrong to do that? I don’t think necessarily it is, but I think personally I’m gonna be a little bit more conservative in terms of how I utilize it in the neoadjuvant setting as well, especially anytime we’re talking about a curative setting, right? Potentially leaving someone with ILD, although it was not seen in the neoadjuvant setting. In the adjuvant setting, it was, right? In terms of fatal deaths from that. So that is a very important point to say, the amount of drug you’re giving at a certain amount of time is also important too.

So I would say if I’m using it in the neoadjuvant setting, I probably am gonna be utilizing T-DM1 at least initially right now in the adjuvant setting right now because I’m a little concerned about the risk of ILD with cumulative toxicity, right? Is what I’m mainly concerned about, really is personally what I feel like. But are there gonna be cases where I may consider the opposite? Absolutely, I think. It just depends on what that scenario looks like after surgery.

Dr. Tarantino: Thank you for that. And yesterday I was talking with my prior mentor, Giuseppe Curigliano from Italy, and he is worked a lot on ESMO guidelines and he was telling me it’s becoming very hard.

This, first of all, changes all the time. And then, there is no right and wrong anymore. There’s not one option, there’s many options. Then it’s an opportunity, but it’s also harder. Our visits, our consults are becoming longer and longer to line up the options and it’s a shared decision making. But at some point, it’s also enough to kind of have to decide on which side to lean on.

And I think we’re gonna see more updates from trials, we’re gonna learn every day more. We’re gonna have more EFS data from DB-11. I think we are gonna understand the landscape better, but definitely we have more options now and we can tailor treatment better and that’s definitely something good.